129
M&A transaction for Pfizer. The big pharma USA has announced that it has reached a definitive agreement to take over the biopharmaceutical company Global Blood Therapeutics. Under the terms of the acquisition, Pfizer will put $ 68.5 per share on the plate, for a total enterprise value of approximately $ 5.4 billion (including debt and net of acquired cash). Both boards of the companies approved the transaction.